You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Express Scripts
Medtronic
Moodys
AstraZeneca

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,402,805

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,402,805 protect, and when does it expire?

Patent 9,402,805 protects CIPRODEX and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.

Summary for Patent: 9,402,805
Title:Method of treating middle ear infections
Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Inventor(s): Wall; G. Michael (Fort Worth, TX), Conroy; Peter J. (Fort Worth, TX)
Assignee: Alcon Pharmaceuticals Ltd. (Fribourg, CH)
Application Number:15/142,225
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,402,805
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,402,805

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis CIPRODEX ciprofloxacin; dexamethasone SUSPENSION/DROPS;OTIC 021537-001 Jul 18, 2003 AB RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ACUTE OTITIS MEDIA   Start Trial
Novartis CIPRODEX ciprofloxacin; dexamethasone SUSPENSION/DROPS;OTIC 021537-001 Jul 18, 2003 AB RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ACUTE OTITIS EXTERNA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,402,805

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 313328   Start Trial
Australia 2002333671   Start Trial
Brazil 0212898   Start Trial
Canada 2459930   Start Trial
China 1231218   Start Trial
China 1555267   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Colorcon
AstraZeneca
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.